Tetrahydrofuran
Medchemexpress LLC Pelcitoclax (APG-1252) | 1619923-36-2 | 99.7% | 1281.85 g·mol⁻¹ | C57H66ClF4N6O11PS4 | 5 MG
Pelcitoclax is a small-molecule dual inhibitor of Bcl-2 and Bcl-xL used in oncology research. It induces apoptosis and has demonstrated antitumor activity in preclinical models, and is supplied with characterized molecular properties and high analytical purity for research applications.
- Dual Bcl-2 and Bcl-xL inhibition mechanism
- Promotes apoptosis in tumor cells
- Demonstrated antitumor activity in preclinical studies
- High analytical purity for consistent results
- Available as solid and ready-to-use DMSO solution formats
eMolecules 64746-04-9 | 2,5-BIS(BROMOMETHYL)TEREPHTHALONITRILE | AstaTech313.980 | C10H6Br2N2 | 95.000 | BrCc1cc(C#N)c(CBr)cc1C#N | 0.1g | 696742362
2,5-BIS(BROMOMETHYL)TEREPHTHALONITRILE | AstaTech | 64746-04-9313.980 | C10H6Br2N2 | 95.000 | BrCc1cc(C#N)c(CBr)cc1C#N | 0.1g | 696742362
Medchemexpress LLC G5-7 10mg | 939681-36-4 | 383.39 g/mol | C22H19F2NO3 | 10 MG
G5-7 is an orally active, allosteric JAK2 inhibitor intended for research use. It selectively inhibits JAK2-mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3, and has been reported to induce cell cycle arrest, apoptosis, and exhibit antiangiogenic effects relevant to glioma studies.
- Allosteric JAK2 inhibitor with selective inhibition of EGFR (Tyr1068) and STAT3 phosphorylation.
- Reported to induce cell cycle arrest and apoptosis in cellular studies.
- Exhibits antiangiogenic activity relevant to glioma research.
- Off-white to light yellow solid powder suitable for research use.
- High purity (99.55%) to support experimental reproducibility.
- Recommended storage: powder at -20°C; in solvent -80°C for 6 months or -20°C for 1 month.
Medchemexpress LLC Mpt0b392 | 1346169-92-3 | 99.6% | 404.44 g/mol | C19H20N2O6S | 10 MG
MPT0B392 is a research-grade microtubule-depolymerizing agent for preclinical studies of tubulin dynamics and cancer drug resistance. It is an orally active quinoline derivative that inhibits tubulin polymerization, activates c-Jun N-terminal kinase (JNK), induces mitotic arrest, and promotes apoptosis. Supplied as a solid or as a 10 mM solution in DMSO for in vitro and in vivo research use.
- Novel microtubule-depolymerizing mechanism supporting tubulin studies.
- Induces JNK activation and mitotic arrest for apoptosis research.
- Available as solid or 10 mM solution in DMSO for flexible dosing.
- High listed purity (99.63%) suitable for biochemical assays.
- Documented molecular weight and formula to aid experimental planning.
Medchemexpress LLC Dalpiciclib 50mg | 1637781-04-4 | 50 MG
Dalpiciclib is an orally active, selective inhibitor of cyclin-dependent kinases CDK4 and CDK6 intended for preclinical research use. It is supplied as a powder and is characterized by CAS 1637781-04-4, molecular formula C25H30N6O2, and molecular weight 446.54 g/mol. For research use only; not for human or clinical use.
- Selective CDK4/6 inhibition with low-nanomolar potency
- High chemical purity suitable for analytical and biological studies
- Supplied as a powder for flexible formulation and dosing
- Stable under recommended storage conditions for long-term use
- Characterized by validated analytical data and CAS identification
![Medchemexpress LLC 2-[[4-(diethylamino)-2-hydroxyphenyl]methylene]hydrazide-4-pyridinecarboxylic acid | 140405-36-3 | 99.7% | 312.37 | C17H20N4O2 | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000247220.png-250.jpg)
Medchemexpress LLC 2-[[4-(diethylamino)-2-hydroxyphenyl]methylene]hydrazide-4-pyridinecarboxylic acid | 140405-36-3 | 99.7% | 312.37 | C17H20N4O2 | 25 MG
RSVA405 is a potent, orally active activator of AMP-activated protein kinase (AMPK) used in preclinical research. It facilitates CaMKKβ-dependent AMPK activation, inhibits mTOR, promotes autophagy and lysosomal degradation of Aβ, and exhibits anti-inflammatory effects via STAT3 inhibition. Activity is observed in vitro (EC50 ≈ 1 μM) and in vivo in metabolic and renal models.
- Potent AMPK activator with an EC50 of approximately 1 μM.
- Promotes autophagy and lysosomal degradation of Aβ.
- Inhibits mTOR and modulates adipocyte differentiation.
- Exhibits anti-inflammatory effects through STAT3 inhibition.
- Demonstrated in vitro and in vivo activity in metabolic and renal models.
- Supplied as a light yellow to yellow solid with high purity.
Medchemexpress LLC Pd-1/pd-l1-in-23 | 2597056-04-5 | 100.0% | 703.41 g/mol | C32H30BrCl2N3O6 | 5 MG
PD-1/PD-L1-IN-23 is a small-molecule inhibitor of the PD-1/PD-L1 immune checkpoint provided as a research reagent. Described as an orally active ester prodrug of L7, it is supplied as a solid suitable for biochemical assays and preclinical studies. CAS 2597056-04-5; molecular formula C32H30BrCl2N3O6; molecular weight 703.41 g/mol.
- Potent small-molecule inhibitor of PD-1/PD-L1 interaction
- Orally active prodrug with demonstrated preclinical activity
- Designed to convert to an active metabolite in vivo
- Solid, white to off-white form with high purity (99.98%)
- Soluble in DMSO; available as solution and powder formats
- Available in multiple research-scale package sizes including 5 mg
Medchemexpress LLC Linzagolix | 935283-04-8 | 99.7% | 508.42 | 100 MG
Linzagolix is a potent, non-peptide, and orally active GnRH antagonist. It can be used for uterine fibroids, endometriosis, and adenomyosis research. For research use only, not for sale to patients.
- Potent GnRH antagonist
- Non-peptide compound
- Orally active
- Used for uterine fibroids research
- Used for endometriosis research
- Used for adenomyosis research
Supply Solutions Burdick & Jackson - Filter Column 8ml (50/PK)
Burdick & Jackson - Filter Column 8ml (50/PK)
Medchemexpress LLC 1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea | 2260969-36-4 | MFCD34579587 | 99.5% | C20H29N3O3S | 10MG
Selnoflast is an orally active, potent, selective, and reversible small-molecule inhibitor of the NLRP3 inflammasome for research use. It is supplied as a white to off-white solid with high reported purity, and the manufacturer provides solubility and storage guidance for preparation and stability in in vitro and preclinical workflows.
- Potent and selective NLRP3 inflammasome inhibition.
- Reversible small-molecule mechanism enabling temporal studies.
- High reported purity for consistent experimental results.
- Solid form suitable for standard laboratory storage and handling.
- Documented solubility in DMSO and alkaline media with preparation notes.
- Specified storage recommendations for powder and solution stability.
- Multiple pack sizes available to support different study scales.
Medchemexpress LLC Linzagolix | 935283-04-8 | 99.7% | 508.4 g/mol | C22H15F3N2O7S | 5 MG
Linzagolix is a non-peptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist used in laboratory research into estrogen-dependent conditions such as uterine fibroids, endometriosis, and adenomyosis. Supplied as a small, high-purity solid for research use only (not for human or veterinary use).
- Non-peptide, orally active GnRH antagonist
- Applicable to uterine fibroids, endometriosis, and adenomyosis research
- High chemical purity suitable for analytical and pharmacological studies
- Supplied in a small 5 mg pack for assay development and pilot studies
- Molecular weight 508.4 g/mol
